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ABSTRACT
Cryptococcemia attributed to non-neoformans cryptococci has not received much attention due to the relative scarcity of reported cases. The 
primary aim of this case report is to highlight several notable characteristics of Cryptococcus laurentii. A 35-year-old woman presented with a right 
supraclavicular mass and a history of low-grade fever. A yeast was isolated from her blood. It formed cream-colored colonies which turned yellowish 
after 72 h of incubation and had a microscopic morphology of elongated budding yeast cells. Its identity was confirmed to be C. laurentii through 
carbohydrate assimilation testing (ID 32 C). The patient responded clinically to fluconazole and cleared the cryptococcemia. She was subsequently 
diagnosed with Hodgkin’s lymphoma through histopathological examination of the supraclavicular mass.
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INTRODUCTION
Non-neoformans cryptococci are generally regarded as non-pathogenic 
saprophytes [1,2]. Moreover, it has also been established that 
Cryptococcus laurentii (a non-neoformans Cryptococcus species) is less 
virulent than Cryptococcus neoformans [3]. However, as the number 
of immunocompromised patients increases, so must the recognition 
that non-neoformans cryptococci can become clinically important 
human pathogens [4]. Although non-neoformans cryptococci can also 
cause serious infections (e.g., central nervous system and bloodstream 
infections), the clinical manifestations are often indistinguishable from 
those attributable to C. neoformans [5]. C. laurentii has been reported to 
have reduced susceptibility to fluconazole [5], a commonly prescribed 
antifungal agent which may be employed to treat C. neoformans 
infections. This case report highlights some notable characteristics 
of C. laurentii which may be important for diagnostic and clinical 
purposes.
CASE REPORT
A 35-year-old woman presented to a tertiary medical center for 
investigation of a right supraclavicular mass. The mass was initially 
a painless and thumb-sized swelling when it was first noticed by 
the patient 5 months back. Subsequently, the mass progressively 
increased in size and became painful. The local symptoms were also 
associated with low-grade fever. On examination, the patient was 
fully conscious, not tachypneic but febrile with a body temperature 
of 37.6°C. A large swelling was noted at her right supraclavicular 
region, measuring 20×15 cm. A sinus was seen to discharge 
hemoserous fluid. The mass was firm and fixed to the overlying skin. 
No other neck masses or lymph nodes were palpable. Examination 
of respiratory, cardiovascular, and other systems was unremarkable. 
A provisional diagnosis of staphylococcal supraclavicular abscess 
was made and she was empirically treated with intravenous 
cloxacillin 500 mg q6h.
Preliminary laboratory investigations of the patient’s blood revealed 
leukocytosis (total white cell count of 21.8×109 cells/L) with evidence 
of neutrophilia (18.1×109 cells/L) and a raised C-reactive protein level 
(9.22 mg/dL). Her retroviral screening was non-reactive. A swab of the 
discharge and a blood specimen were sent for microbiological culture. 
The supraclavicular mass was also biopsied for histopathological 
examination. After 4 days of incubation, the blood specimen in 
the BACTEC Myco/F Lytic vial was positive for microbial growth. 
A Gram stain revealed elongated and budding yeast cells with no 
pseudohyphae. The yeast was cultured on Sabouraud dextrose 
agar (SDA) and cream-colored colonies were observed after 48 h of 
incubation at 35°C, which turned yellowish after 72 h. On cornmeal 
agar, elongated and budding yeast cells were observed under the light 
microscope (Fig. 1). Through carbohydrate assimilation tests (ID 32 
C; bioMerieux, France), the yeast was finally identified as C. laurentii 
(numerical profile: 5777377371, 99.0% identification). The swab 
specimen grew coagulase-negative staphylococci and the bacteria 
were regarded as skin contaminants.
Following the release of the blood culture report, intravenous 
cloxacillin was discontinued after 6 days and a course of intravenous 
fluconazole 400 mg OD was started. A follow-up blood culture after 
a week of fluconazole treatment was negative for both bacteria and 
fungi. The patient responded clinically to the antifungal therapy and 
was allowed home after completing a 2-week course of fluconazole. 
Two weeks post-admission, the histopathological report for the 
supraclavicular mass (lymph node) provided a diagnosis of classical 
Hodgkin’s lymphoma. Fungal stains (i.e., periodic acid-Schiff and 
Grocott-Gomori methenamine silver) did not reveal the presence of any 
fungal elements/bodies in the tissue specimen.
DISCUSSION
Non-neoformans cryptococci are encapsulated yeasts with a 
worldwide prevalence and they can be isolated from numerous 
environmental sources and foods [5]. The term “non-neoformans 
cryptococci” traditionally refers to Cryptococcus spp. other than 
C. neoformans and Cryptococcus gattii because the latter was 
previously considered a variant of C. neoformans [4]. Approximately 
80% of non-neoformans cryptococcal infections are caused by 
C. laurentii and Cryptococcus albidus [4]. Most cases of non-
neoformans cryptococcal fungemia are nosocomially acquired 
and the presence of invasive devices is a significant predisposing 
factor particularly when associated with C. laurentii infections [6]. 
Although in the present case, the patient did not have any indwelling 
medical device (e.g., central venous line), by having a hematological 
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malignancy (i.e., lymphoma), her cell-mediated immunity could have 
been compromised, leading to the C. laurentii cryptococcemia [4]. 
Although C. laurentii fungemia has been reported before in patients 
with underlying non-Hodgkin’s lymphoma [4,7], to the best of our 
knowledge, there has been no report associating the infection with 
classical Hodgkin’s disease.
Although C. laurentii is India Ink positive and produces urease, these 
characteristics are common to all cryptococci. However, the capsule of 
C. laurentii in the India Ink mount is narrow/slight [1,8]. Furthermore, 
its microscopic morphology is that of elongated and budding yeast 
cells [9] rather than the globose yeast cells which are more typical of C. 
neoformans and C. gattii. Another clue to the presence of C. laurentii is 
yellow (or orange) colonies on SDA, especially after extended incubation 
[10]. A negative caffeic acid test is another supplementary test which 
would distinguish C. laurentii from C. neoformans [8]. Non-neoformans 
cryptococci are less likely to produce positive results in cryptococcal 
antigen detection tests [4], and thus, glucuronoxylomannan antigen 
assays should not be relied on to diagnose cases of C. laurentii fungemia. 
For laboratories without molecular identification (i.e., DNA sequencing) 
capabilities, commercial carbohydrate assimilation kits for yeasts such 
as ID 32 C (bioMerieux, France) may be utilized [8].
There are no established guidelines for the treatment of infections caused 
by C. laurentii [9,10]. However, with regard to the in vitro susceptibility 
profile of C. laurentii, a study on 39 isolates revealed that amphotericin 
B was the most active compound, fluconazole had limited activity, and 
flucytosine as well as echinocandins were inactive [2]. In contrast, 
fluconazole resistance has been virtually absent in C. neoformans 
isolates from Asia [11]. Admittedly, we did not perform antifungal 
susceptibility testing on our C. laurentii isolate because there were no 
published Clinical and Laboratory Standards Institute breakpoints for 
the antifungal susceptibility testing of cryptococci. We were, however, 
fortunate that our patient responded clinically to fluconazole. Other 
authors have also reported positive outcomes with fluconazole therapy, 
either as a sole therapeutic agent [9] or as a subsequent antifungal agent 
following amphotericin B therapy [1]. Other azoles (e.g., voriconazole) 
were also used successfully to treat infections caused by C. laurentii [10]. 
The recent discovery of new antifungal compounds from plants such as 
fenugreek and clove basil could also potentially expand the antifungal 
arsenal against C. laurentii [12,13].
CONCLUSION
All clinical microbiology laboratories should attempt to identify 
non-neoformans cryptococci to the species level to aid therapeutic 
decisions. Due to the unpredictable fluconazole susceptibility profile, 
the threshold to switch to amphotericin B should be low for patients 
with C. laurentii infections who are initially managed with fluconazole.
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Fig. 1: Microscopic morphology of Cryptococcus laurentii cultured 
on cornmeal agar
